Filing Flows › Insulet (PODD) › Q2 2026
Insulet (PODD) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
Insulet (PODD) reported revenue of $802M for the second quarter 2026 (Q2 2026), +24% from a year earlier and +5% from the quarter before. Operating margin was 16.2%, net earnings $95.0M (11.8% of revenue).
Insulet, Q2 2026: revenue $802M (+24% year over year), operating margin 16.2%, net earnings $95.0M, operating cash flow $88.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $802M | +5% | +24% |
| Gross profit | $563M | +6% | +24% |
| Operating profit | $130M | +6% | +7% |
| Net earnings | $95.0M | +4% | +322% |
| Operating cash flow | $88.4M | -22% | -55% |
| Free cash flow | $55.9M | -38% | -69% |
What changed
Revenue was $801.7M in Q2 2026, up 24% year over year and up 5% from the previous quarter. U.S. was the largest line at 68% of revenue. U.S. added $90.9M year over year (up 20%), 60% of the total change. Drug Delivery declined 43%.
Gross margin was 70.2%, up 0.5 points from Q2 2025. Operating profit was $129.7M, a 16.2% margin (down 2.5 points year over year). Of the extra revenue versus Q2 2025, 6% reached operating profit, below the 19% margin then. Operating expenses grew 31% against revenue growth of 24%. The fastest-growing cost line was SG&A (+34%). Net earnings were $95.0M, up 322% year over year. The effective tax rate was 20.0%.
Operating cash flow was $88.4M (down 55% year over year), 93% of net earnings. Non-cash charges added back $26.7M of depreciation and amortization and $19.6M of share-based compensation. Working capital and other items used $52.9M. Capital expenditures of $32.5M left free cash flow of $55.9M.
Questions
What was Insulet's revenue in the second quarter 2026?
Insulet (PODD) reported revenue of $802M for the second quarter 2026 (Q2 2026), +24% from a year earlier and +5% from the quarter before.
Was Insulet profitable in the second quarter 2026?
Operating profit was $130M (16.2% of revenue) and net earnings $95.0M.
Source: Insulet 10-Q on SEC EDGAR.